SUBSCRIBE
SUBSCRIBE
News   Drug Development

GlaxoSmithKline’s Pazopanib Shows Promise in Ovarian Cancer

September 15, 2008 | 
1 min read

LONDON, Sept 15 (Reuters) - GlaxoSmithKline’s experimental drug pazopanib appears to be effective in fighting ovarian cancer, based on measurements of a biological marker used to predict tumour recurrence, researchers said on Monday.

Clinical research Phase II Europe
MORE ON THIS TOPIC
Concept art of a gene therapy showing a syringe injecting into a 3D DNA helix
Gene therapy
7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Photo of Carlos Doti, vice president and head of medical affairs for the U.S. oncology business unit at AstraZeneca
People
From Argentina to America: A Physician’s Journey to Pharma and AstraZeneca
October 10, 2024
 · 
6 min read
 · 
Angela Gabriel
Podcast
BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
October 9, 2024
 · 
1 min read
 · 
Heather McKenzie
South San Francisco, CA, USA - May 1, 2022: Exterior view of the Merck Researches Laboratories in South San Francisco, California. Merck & Co., Inc. is a global pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada.
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
October 8, 2024
 · 
2 min read
 · 
Kate Goodwin